Research programme: leptin mimetics - AstraZeneca

Drug Profile

Research programme: leptin mimetics - AstraZeneca

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge Biotechnology
  • Developer AstraZeneca
  • Class Small molecules
  • Mechanism of Action Leptin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in United Kingdom (PO)
  • 23 Dec 2009 AstraZeneca acquires leptin modulator programme for obesity from Biovitrum
  • 23 Nov 2009 Cambridge Biotechnology has been acquired by Proximagen Neuroscience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top